628 results on '"Chaft, Jamie E."'
Search Results
102. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
103. Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease
104. Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
105. Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
106. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
107. Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
108. Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer.
109. Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
110. LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.
111. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy.
112. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
113. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
114. Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer
115. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
116. A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial
117. Corrigendum to “Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions” [Lung Cancer 159 (2021) 66–73]
118. Adaptive Neoadjuvant Chemotherapy Guided by 18F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial
119. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
120. Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers
121. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
122. Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC
123. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers
124. Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
125. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
126. 76 FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR THE TREATMENT OF IMMUNE-MEDIATED DIARRHEA AND COLITIS: A CASE SERIES
127. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
128. Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer
129. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
130. Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
131. Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers
132. Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
133. Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung
134. ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma
135. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
136. Clinical outcomes, local–regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab
137. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers
138. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
139. CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
140. Locoregional control, failure patterns and clinical outcomes in patients with stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
141. MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA.
142. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
143. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
144. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
145. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
146. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
147. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.
148. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
149. Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC
150. Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.